{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"785.0"},{"groupId":"OG001","value":"1010"},{"groupId":"OG002","value":"1190"},{"groupId":"OG003","spread":"136","value":"2726"},{"groupId":"OG004","spread":"72","value":"5111"},{"groupId":"OG005","spread":"133","value":"8470"},{"groupId":"OG006","spread":"281","value":"6401"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"4"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"466.0"},{"groupId":"OG001","value":"547.0"},{"groupId":"OG002","value":"508.0"},{"groupId":"OG003","spread":"42","value":"2035"},{"groupId":"OG004","spread":"329","value":"3130"},{"groupId":"OG005","spread":"97","value":"10050"},{"groupId":"OG006","spread":"159","value":"10540"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"4"}],"units":"Participants"}],"title":"Cycle 2 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"4"}],"units":"Participants"}],"description":"AUClast was area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"PF-06952229 was administered at a dose of 20 mg orally twice daily (BID) for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG000","title":"Part 1A: PF-06952229 20mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 40 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG001","title":"Part 1A: PF-06952229 40mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 80 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG002","title":"Part 1A: PF-06952229 80mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 150 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG003","title":"Part 1A: PF-06952229 150mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 250 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG004","title":"Part 1A: PF-06952229 250mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 375 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG005","title":"Part 1A: PF-06952229 375mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 500 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG006","title":"Part 1A: PF-06952229 500mg Monotherapy"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Participants with advanced/metastatic tumors in PF-06952229 single agent dose escalation phase, who had sufficient information to estimate at least 1 of the PK parameters of interest. Here, \"number analyzed\" signifies participant evaluable for each row.","reportingStatus":"POSTED","timeFrame":"0 (pre dose), 0.5, 1, 2, 4, 6 and 12 hours (post dose) on Day 1 of cycle 1 and cycle 2","title":"Area Under the Plasma Concentration-Time Profile From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of PF-06952229 (Part 1A)","type":"SECONDARY","unitOfMeasure":"nanograms*hour/milliliter (ng*hr/mL)"}